AVROBIO, Inc. is a phase II clinical stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its product pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03 and AVR-RD-04. The Company is developing AVR-RD-01 for the treatment of Fabry disease. AVR-RD-02 is the Company’s gene therapy for Gaucher disease. AVR-RD-03 is being developed for the treatment of Pompe disease. The Company is developing AVR-RD-04 for the treatment of patients with cystinosis.